PT148.S3.Q17 > Analytics

SECTION 1 · lr

Question 1 Question 2 Question 3 Question 4 Question 5 Question 6 Question 7 Question 8 Question 9 Question 10 Question 11 Question 12 Question 13 Question 14 Question 15 Question 16 Question 17 Question 18 Question 19 Question 20 Question 21 Question 22 Question 23 Question 24 Question 25

SECTION 2 · rc

PASSAGE 1

Question 1 Question 2 Question 3 Question 4 Question 5 Question 6

PASSAGE 2

Question 7 Question 8 Question 9 Question 10 Question 11 Question 12 Question 13

PASSAGE 3

Question 14 Question 15 Question 16 Question 17 Question 18 Question 19

PASSAGE 4

Question 20 Question 21 Question 22 Question 23 Question 24 Question 25 Question 26 Question 27

SECTION 3 · lr

SECTION 4 · lr

The government will not pay for patients to take Antinfia until the manufacturer provides information about the drug’s cost-effectiveness. This information can only be obtained by performing massive clinical trials. The trials cannot be performed until the drug is in widespread circulation, which will happen only if the government pays for Antinfia.

Government pays → provide detailed info → massive clinical trails → widespread circulation → government pays

This chain is circular, and the stimulus says the government is not paying. You can run the contrapositive back and draw any valid inference along the chain. (no widespread circulation, no clinical trials, no detailed info)

This is too broad to support. The stimulus is purely focused on Antinfia, not “any medicine”

The stimulus says that the drug will be in wide circulation only if the government pays. The government is refusing to pay. Thus, it will never be in wide circulation.

The stimulus does not give any information about whether patients will pay out of pocket or not. You need to make some assumptions to make this work

The stimulus does not say whether the government should/should not pay for Antinfia. It only explains what barriers the drug is facing to becoming widely available.

The stimulus does not say whether Antinfia is/is not cost-effective. The stimulus only notes that the drug company cannot yet provide information about its cost-effectiveness.

Question

83% of people who answer get this correct

This is a moderately difficult question.

CURVE

Score of students with a 50% chance of getting this right

25% 141

148

75% 156

Question Stem Tags

Most strongly supported

Stimulus Tags

Conditional reasoning

Popularity Avg. score

154

83%

164

156

154

You don't have any history with this question.. yet!

PrepTest 148 - Section 3 - Question 17

Difficulty

Analysis

Answer Popularity

Question history

Confirm action